Open Collections

UBC Faculty Research and Publications

New drugs IV Therapeutics Initiative (University of British Columbia)

Description

Therapeutics Letter 26 examines benefits and harms of newer drugs donepezil, levofloxacin, pantoprazole, and quetiapine. Donepezil slightly improves a measure of cognitive function and a clinician’s global assessment of change in patients with Alzheimer’s disease. Levofloxacin is similar to ofloxacin in all respects except that it is twice as potent. Pantoprazole is a proton pump inhibitor that is similar in efficacy, safety, cost and convenience to lansoprazole and omeprazole. Quetiapine has similar efficacy and a different side effect profile to haloperidol and chlorpromazine in 6-week trials. More and better evidence is required to demonstrate the long-term effectiveness and safety of new atypical antipsychotics.

Item Metadata

Title
New drugs IV
Alternate Title
Therapeutics Letter 26
Creator
Therapeutics Initiative (University of British Columbia)
Date Issued
1998-10
Description
Therapeutics Letter 26 examines benefits and harms of newer drugs donepezil, levofloxacin, pantoprazole, and quetiapine. Donepezil slightly improves a measure of cognitive function and a clinician’s global assessment of change in patients with Alzheimer’s disease. Levofloxacin is similar to ofloxacin in all respects except that it is twice as potent. Pantoprazole is a proton pump inhibitor that is similar in efficacy, safety, cost and convenience to lansoprazole and omeprazole. Quetiapine has similar efficacy and a different side effect profile to haloperidol and chlorpromazine in 6-week trials. More and better evidence is required to demonstrate the long-term effectiveness and safety of new atypical antipsychotics.
Subject
Alzheimer Disease; Antipsychotic Agents; Donepezil; Drug-Related Side Effects and Adverse Reactions; Levofloxacin; Pantoprazole; Proton Pump Inhibitors; Quetiapine Fumarate
Genre
Other
Type
Text
Language
eng
Notes
The UBC TI is funded by the BC Ministry of Health to provide evidence-based information about drug therapy. We neither formulate nor adjudicate provincial drug policies.
Date Available
2023-06-20
Provider
Vancouver : University of British Columbia Library
Rights
Attribution-NonCommercial-NoDerivatives 4.0 International
DOI
10.14288/1.0433605
URI
http://hdl.handle.net/2429/85015
Affiliation
Medicine, Faculty of; Anesthesiology, Pharmacology and Therapeutics, Department of
Peer Review Status
Reviewed
Scholarly Level
Faculty; Researcher
Rights URI
http://creativecommons.org/licenses/by-nc-nd/4.0/
Aggregated Source Repository
DSpace

Item Media

Item Citations and Data

Rights

Attribution-NonCommercial-NoDerivatives 4.0 International